Insider Transactions in Q4 2025 at Royalty Pharma PLC (RPRX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2025
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
69,594
-7.37%
|
$2,714,166
$39.3 P/Share
|
|
Nov 07
2025
|
Marshall Urist EVP, Research & Investments |
BUY
Conversion of derivative security
|
Indirect |
160,000
+43.64%
|
-
|
|
Nov 05
2025
|
Marshall Urist EVP, Research & Investments |
BUY
Grant, award, or other acquisition
|
Direct |
4,626
+9.54%
|
-
|
|
Nov 05
2025
|
Christopher Hite EVP & Vice Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
6,168
+0.93%
|
-
|
|
Nov 05
2025
|
George W. Lloyd EVP, Investments & CLO |
BUY
Grant, award, or other acquisition
|
Indirect |
6,168
+9.54%
|
-
|
|
Nov 05
2025
|
Terrance P. Coyne EVP & CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
6,168
+9.54%
|
-
|
|
Nov 05
2025
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
36,559
+3.74%
|
-
|